Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8191 to 8205 of 8796 results

  1. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued Reference number: GID-TA10242

    Technology appraisal guidance
    Discontinued

  2. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued Reference number: GID-TA10264

    Technology appraisal guidance
    Discontinued

  3. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

    Discontinued Reference number: GID-TA10297

    Technology appraisal guidance
    Discontinued

  4. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued Reference number: GID-TA10308

    Technology appraisal guidance
    Discontinued

  5. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued Reference number: GID-TA10320

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

    Technology appraisal guidance
    Discontinued

  7. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued Reference number: GID-TA10329

    Technology appraisal guidance
    Discontinued

  8. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued Reference number: GID-TA10337

    Technology appraisal guidance
    Discontinued

  9. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued Reference number: GID-TA10338

    Technology appraisal guidance
    Discontinued

  10. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  11. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued Reference number: GID-TA10355

    Technology appraisal guidance
    Discontinued

  12. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued Reference number: GID-TA10365

    Technology appraisal guidance
    Discontinued

  13. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued Reference number: GID-TA11004

    Technology appraisal guidance
    Discontinued